The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites.
The letters cite violations including claims implying compounded products are the same as FDA-approved drugs, and advertising products under a telehealth firm’s name or trademark without clarifying the compounder. The FDA said compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing, according to a March 3 agency news release.
The action marks the second group of warning letters sent to telehealth firms since the agency launched a crackdown in September on misleading direct-to-consumer pharmaceutical advertisements. Over the past six months, the FDA said it has sent thousands of letters to pharmaceutical and telehealth firms — more than were sent over the entire preceding decade.
FDA Commissioner Marty Makary, MD, said in the news release the agency is monitoring misleading claims across media platforms and taking action.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.